Accelerating Inhalation Product Development: Integrated Formulation and Analytical Services by Via Therapeutics
Developing Orally Inhaled and Nasal Drug Products (OINDP) is a complex process where formulation, particle properties, and device performance are inextricably linked. Success demands a partner who can navigate these challenges with precision and speed.
​
Via Therapeutics provides a fully integrated service continuum, from early-stage formulation development to critical analytical testing. Our unique approach combines novel processing methodologies with rapid, expert characterization to accelerate your program from concept to clinic.
The Via Therapeutics Advantage: Speed for Early-Stage Success
In the fast-paced world of drug development, speed and data quality are critical. This is especially true during the early formulation and device selection stages, where quick feedback loops can save months of development time and significant cost.
​
Our services are built for this reality. We specialize in rapid method development, allowing us to provide critical data on your formulation's performance quickly. This agility empowers our clients to make informed, data-driven decisions faster, de-risking their programs and identifying lead candidates with greater confidence.
Expert Inhalation and Nasal Product Testing Services
Via Therapeutics provides a comprehensive suite of analytical services for a wide array of nasal and inhalation products, including dry powder inhalers (DPIs), pressurized metered-dose inhalers (pMDIs), and nasal sprays.
Aerodynamic Particle Size Distribution (APSD) by NGI
A Critical Quality Attribute (CQA) for all inhaled products, APSD determines where the drug particles will deposit in the respiratory tract. Our team has extensive experience performing APSD testing using the industry-standard Next Generation Impactor (NGI) for a variety of nasal and inhaler devices.
Delivered Dose Uniformity (DDU)
We provide robust testing to ensure that the patient receives a consistent and accurate therapeutic dose with every actuation, from the first to the last dose in the device. This is essential for regulatory compliance and patient safety.
Integrated Formulation & Processing Services
Our analytical services are perfectly complemented by our advanced processing and formulation capabilities. This seamless integration allows you to move directly from particle engineering to performance testing, all under one roof. Our formulation development services include:
-
Jet Milling: Expert micronization to achieve target particle size distributions essential for deep lung or nasal delivery.
-
Spray Drying: A flexible platform for engineering complex particles, creating amorphous solid dispersions, or manufacturing novel powder formulations with specific properties.
-
Novel Methodologies: We leverage a suite of proprietary and novel processing technologies to tackle even the most difficult formulation challenges.
Partner with Via Therapeutics
Shorten your development timelines and gain deeper insight into your product's performance. Partner with Via Therapeutics for an integrated, rapid, and expert approach to inhalation and nasal product development.
Figure 1: The Next Generation Impactor (NGI) at Via Therapeutics, ready for Aerodynamic Particle Size Distribution (APSD) testing.")
